Résumé
Purpose. - To evaluate the implementation of clinical guideline for the use of antimicrobial agents in febrile neutropenia in the Île-de-France Network of Pediatric Hematology-Oncology (RIFHOP) and the incidence of documented infections in febrile neutropenia. Patients and methods. - Prospective observational multicenter study in children treated for solid tumors or hematologic malignancies with febrile neutropenia after conventional chemotherapy in Pediatric unit of RIFHOP over a period of 6 months. Results. - One hundred and seventy-six febrile neutropenia occurred in 144 children (77 malignancies - 67 solid tumors). Guideline for first-line antimicrobial treatment was followed in 91% of cases. Antimicrobial treatment has been adapted according to the guidelines of RIFHOP in 88% of cases and the recommendations for the management of outpatients were observed in 87 % of febrile neutropenia. Microbiological documentation was found in 33.5% with a prevalence of urinary tract infection (Escherichia coli). Conclusions. - The feasibility and effectiveness of these guidelines seem to be excellent with an incidence of documented infection comparable to the literature.
Titre traduit de la contribution | Clinical practice guideline for the use of antimicrobial agents in neutropenic children with cancer: Experience of the RIFHOP |
---|---|
langue originale | Français |
Pages (de - à) | 132-140 |
Nombre de pages | 9 |
journal | Revue d'Oncologie Hematologie Pediatrique |
Volume | 2 |
Numéro de publication | 3 |
Les DOIs | |
état | Publié - 1 sept. 2014 |
mots-clés
- Antimicrobial agents
- Cancer
- Childhood
- Neutropenia